Avid Bioservices Inc (CDMO)

[keep_trying]

CJ, one of the most positive call outs from today's news from PPHM is that their investigation of the 2nd line NSCLC trial coding error determined that the review trial results have a basis for presentation to the FDA. PPHM says they are very pleased with the indicated performance from the 3 mg/kg Bavi arm relative to the combined 0 and 1 mg/kg new control arm.

The study results still carry the basis for a visit with the FDA to discuss a Phase 3 trial design, with or without a partner.
Bavi is still outperforming SOC, this time with one hand tied behind their back by grouping some low dose Bavi in with Placebo. In that sense, Dew is being shown a context in which he was right (1 mg/kg Bavi = placebo in the new control arm, LOL!). But then again, ..... PPHM is suggesting Bavi is performing so well it is indicating good results relative to SOC even when a lower Bavi dose is mixed in with the control arm. Remarkable.

Will those millions of $2.50 call options due to expire at the end of next week end up being in the money? That would be nice for Ayer and longs alike.

Best wishes and IMO.
KT